## **Product** Data Sheet

# (S,R,S)-AHPC-Me hydrochloride

Cat. No.: HY-42424 CAS No.: 1948273-03-7 Molecular Formula:  $C_{23}H_{33}CIN_4O_3S$ 

481.05 Molecular Weight:

Target: Ligands for E3 Ligase

Pathway: **PROTAC** 

Storage: -20°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

#### **SOLVENT & SOLUBILITY**

In Vitro

H<sub>2</sub>O: 100 mg/mL (207.88 mM; Need ultrasonic)

DMSO:  $\geq$  63 mg/mL (130.96 mM)

\* "≥" means soluble, but saturation unknown.

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 2.0788 mL | 10.3939 mL | 20.7879 mL |
|                              | 5 mM                          | 0.4158 mL | 2.0788 mL  | 4.1576 mL  |
|                              | 10 mM                         | 0.2079 mL | 1.0394 mL  | 2.0788 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: PBS Solubility: 100 mg/mL (207.88 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.32 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.32 mM); Suspended solution; Need ultrasonic
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.32 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description

(S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein<sup>[1]</sup>. (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a  $DC_{50} < 1 \text{ nM}^{[2]}$ .

| IC <sub>50</sub> & Target      | VHL   |
|--------------------------------|---|
|                                |   |
| REFERENCES                     |   |
| [1]. WO/2017/030814A1          |   |
| [2]. Raina K, et al. PROTAC-ii | nduced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9.                         |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                | Caution: Product has not been fully validated for medical applications. For research use only.  Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com |
|                                | Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA  |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |
|                                |   |